Skip to main content
Kairos Pharma, LTD. logo

Kairos Pharma, LTD. — Investor Relations & Filings

Ticker · KAPA ISIN · US48301N1046 US Professional, scientific and technical activities
Open in API
Filings indexed 112 across all filing types
Latest filing 2026-06-04 Regulatory Filings
Country US United States of America
Listing US KAPA

About Kairos Pharma, LTD.

https://kairospharma.com

Kairos Pharma, LTD. is a clinical-stage biopharmaceutical company developing novel oncology therapeutics. The company's primary focus is on overcoming key hurdles in cancer treatment, specifically drug resistance and immune suppression. Its lead product candidate, ENV105, is an antibody that targets the CD105 protein to reverse resistance to existing cancer drugs. ENV105 is in mid-stage clinical trials for prostate cancer and early-stage trials for lung cancer. In addition, Kairos is developing a pipeline of immunotherapies designed to reverse cancer-induced immune suppression. This includes KROS101, a small molecule to enhance T cell activity, and KROS201, a T cell therapy targeting cancer stem cells in glioblastoma, for which an Investigational New Drug (IND) application has been cleared.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 90% confidence The document is a United States SEC Form 8-K “Current Report” filed under Section 13 or 15(d) of the Securities Exchange Act of 1934, disclosing “Other Events” and furnishing a press release as Exhibit 99.1. It is the actual Form 8-K filing rather than a full annual or interim financial report, earnings release, or management presentation. Therefore, it is classified as a general regulatory filing under our taxonomy.
2026-06-04 English
DEFA14A
Proxy Solicitation & Information Statement
2026-05-26 English
ARS
Annual Report FY 2025
2026-05-22 English
DEF 14A
Proxy Solicitation & Information Statement
2026-05-22 English
8-K
Report Publication Announcement Classification · 89% confidence The text is a Form 8-K “Current Report” describing that the company has issued and is furnishing an investor presentation as Exhibit 99.1. The document itself does not contain the presentation’s content but simply announces its publication and attachment. Under the menu vs. meal rule, this is an announcement of a report’s release rather than the report itself, fitting the Report Publication Announcement category.
2026-05-18 English
10-Q - Kairos Pharma, LTD. (0001962011) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-13 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.